Schrodinger Inc. (SDGR) News

Schrodinger Inc. (SDGR): $31.95

0.31 (-0.96%)

POWR Rating

Component Grades








Add SDGR to Watchlist
Sign Up

Industry: Medical - Services




#64 of 66

in industry

Filter SDGR News Items

SDGR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SDGR News Highlights

  • SDGR's 30 day story count now stands at 4.
  • Over the past 26 days, the trend for SDGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG and VIEW are the most mentioned tickers in articles about SDGR.

Latest SDGR News From Around the Web

Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. | December 6, 2023

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, November 17, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050 shares of the company’s common stock to 13 newly hired employees. These grants were m

Yahoo | November 17, 2023

3 Cutting-Edge Biotech Stocks for the Bold Investor

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks.

Josh Enomoto on InvestorPlace | November 14, 2023

AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence

We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.

Ian Cooper on InvestorPlace | November 10, 2023

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK, November 06, 2023--Schrödinger today announced that management will participate in two conferences in November.

Yahoo | November 6, 2023

3 Top Publicly Traded Companies Leading the AI Revolution

With recent data indicating AI is saving companies loads of money, three AI stocks to buy are exploiting this trend.

Larry Ramer on InvestorPlace | November 4, 2023

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript November 1, 2023 Schrödinger, Inc. misses on earnings expectations. Reported EPS is $-0.86 EPS, expectations were $-0.69. Operator: Welcome to Schrödinger’s Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today’s call. All lines have been […]

Yahoo | November 2, 2023

Q3 2023 Schrodinger Inc Earnings Call

Q3 2023 Schrodinger Inc Earnings Call

Yahoo | November 2, 2023

Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

NEW YORK, November 02, 2023--Schrödinger today announced that new data on SGR-1505, its MALT1 inhibitor, and SGR-2921, its CDC7 inhibitor, will be presented at ASH.

Yahoo | November 2, 2023

Is Schrödinger Stock a Buy Now?

With the frothiness of the artificial intelligence (AI) craze in full swing, Schrödinger (NASDAQ: SDGR) is a biotech that investors should know about now. While many questions remain about the viability of its business model and its ability to grow in the long term in the face of mounting competition, for the moment it's one of the leaders in the field of information technology-driven drug development. Schrödinger is a leader in the field of technology-assisted drug discovery and development.

Yahoo | November 2, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!